Welcome to our dedicated page for Crescita Therape news (Ticker: CRRTF), a resource for investors and traders seeking the latest updates and insights on Crescita Therape stock.
Crescita Therapeutics Inc. (OTC US: CRRTF; TSX: CTX) is a Canadian commercial dermatology company that regularly issues detailed news releases about its operations, financial performance and strategic agreements. As a company with in-house R&D and manufacturing capabilities and three defined segments—Commercial Skincare, Licensing and Royalties, and Manufacturing and Services—its news flow covers a range of topics relevant to investors and industry observers.
Readers of this news page can expect recurring coverage of quarterly and annual financial results, where Crescita reports revenue by segment, gross profit, operating expenses, net income or loss, and non-IFRS measures such as EBITDA and Adjusted EBITDA. These releases often explain how performance in the Skincare, Licensing and Manufacturing segments contributed to overall results and describe factors such as contract manufacturing volumes, licensing payments related to Pliaglis®, and sales of branded skincare products.
Crescita’s news also highlights licensing and distribution developments for Pliaglis, including commercialization and development license agreements, exclusive distribution agreements in specific territories, and changes such as the mutual termination of a licensing agreement with Croma Pharma GmbH and the resulting reversion of rights to Crescita. Updates on regulatory pathways for Pliaglis in markets such as China, through partners responsible for clinical trials and approvals, appear in these communications.
Another recurring theme is contract manufacturing and strategic asset acquisitions. The company has announced an amended contract manufacturer supply agreement with a global skincare client, an exclusive manufacturing and supply agreement with a Canadian healthcare services provider for sanitary products, and acquisitions of assets from Occy Laboratoire Inc. and Laboratoire Provence-Canada Inc. News items describe how these arrangements affect manufacturing volumes, plant utilization and the product and client base.
Additional releases cover corporate actions and governance, such as approvals and activity under normal course issuer bids, results of annual general and special meetings of shareholders, and participation in investor conferences. For ongoing insight into Crescita’s financial performance, partnerships and manufacturing activities, this page aggregates the company’s official news in one place.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Crescita Therapeutics (CRRTF) reported a record annual revenue of $23.5M for fiscal year 2022, a 40% increase from 2021. Adjusted EBITDA rose by 138% to $2.2M. In Q4 2022, revenue was $6.03M, a 20% decline from Q4 2021, primarily due to lower licensing revenues. However, gross profit for the year grew 32% to $13.18M despite a slight decrease in gross margin. Cash reserves fell to $8.23M from $11.33M. The company launched ART FILLER in Q1 2023, aiming to enhance its skincare portfolio. Management highlighted growth in the manufacturing segment and successful product launches.
Crescita Therapeutics reported remarkable financial results for Q3-F2022, with revenue increasing to $6.0M, up from $3.0M in Q3-F2021, driven by a significant boost in manufacturing revenue of $4.3M. The company's Adjusted EBITDA improved to $0.5M, marking a turnaround from a loss of $0.5M the previous year. Additionally, cash reserves stood at $10.7M. The President and CEO, Serge Verreault, highlighted the company’s continued growth with plans to launch ART FILLER® injectables in early 2023. The gross margin slightly declined to 48.7% from 51.0%.
Crescita Therapeutics Inc. (CRRTF) reported a significant 120% sales growth in Q2-F2022, with revenues reaching $6.5M, up from $2.9M in Q2-F2021. The company achieved a record manufacturing revenue of $3.9M and an Adjusted EBITDA of $0.6M, improving by $0.9M year-over-year. Despite repaying $1.0M in convertible debentures, cash balances at $10.5M decreased by $1.2M for the quarter. The approval of ART FILLER® injectables is set to enhance Crescita's portfolio, with plans for a Q4 2022 launch.
Crescita Therapeutics Inc. held its 2022 Annual General and Special Meeting in Laval, Quebec, where significant shareholder decisions took place. The election of directors showed strong support, with Daniel N. Chicoine receiving 96.9% of votes for his position. Ernst & Young LLP was reappointed as the external auditor with 99.7% approval. Additionally, Crescita's Shareholder Rights Plan was approved, garnering 97.5% of votes. The meeting emphasized the company's commitment to growth and innovation in the dermatology sector.
Crescita Therapeutics Inc. (CRRTF) reported Q1-F2022 revenue of $4,951K, a 52% increase from Q1-F2021. Manufacturing segment revenue reached a record $3,415K, significantly improving from $692K last year. Gross profit rose to $2,712K, though gross margin fell to 54.8%. Operating expenses increased to $3,088K driven by higher SG&A costs. Adjusted EBITDA decreased to $66K. Cash and cash equivalents improved to $11,742K. The company plans expansion into 35 new countries for Pliaglis and launched a new Obagi Medical product line in Canada, enhancing its portfolio.
Crescita Therapeutics Inc. (TSX: CTX, OTC US: CRRTF) announced CEO Serge Verreault will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 3, 2022, at 10:30 a.m. in Hall A at the Metro Toronto Convention Centre. The conference, occurring on May 2-3, features around 60 leading healthcare companies from Canada. Verreault will outline Crescita’s recent business highlights and growth strategy, with the management team available for one-on-one investor meetings. For more details, visit bloomburton.com/conference.